Comments
Drugmakers Cipla and Sun Pharma have signed non-exclusive patent license agreements with Takeda Pharmaceutical Company Limited, respectively, for ‘Vonoprazan’ for India. The drug is used to treat acid-related illnesses among patients.
Cipla and Sun Pharma will independently commercialise the drug in India under their respective trademark brands. Earlier this month, Torrent Pharma had also inked a similar agreement on the same drug.
Vonoprozan (oral tablets) is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of Gastroesophageal Reflux Disease (GERD). Vonoprozan is also used in treating disorders such as erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis and Helicobacter pylori eradication, a note from Cipla said.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.